/ /

  • linkedin
  • Increase Font
  • Sharebar

    SLT effective part of glaucoma care strategy in developing countries

    Benefits for OAG in Afro-Caribbean population sustained over 3 years without medical therapy


    Take Home

    Selective laser trabeculoplasty provided a majority of Afro-Caribbean patients with a mean IOP reduction of 40% with no need for medical therapy.



    Morgantown, WVSelective laser trabeculoplasty (SLT) may prove beneficial to patients with glaucoma in the African-derived developing world, as part of a research program to identify cost-effective strategies for glaucoma care.

    “The magnitude of IOP reduction following SLT is significant, on the order of 35% to 40%,” said Tony Realini, MD, MPH, associate professor of ophthalmology, West Virginia University Eye Institute, Morgantown, WV. “This result is at least as good as—and perhaps better than—the results expected with a prostaglandin analogue.”

    In case you missed it: Quantel's Optimus Fusion receives FDA 510(k) clearance

    The St. Lucia Study

    In a prospective cohort study of the effects of SLT in open-angle glaucoma (OAG) in an Afro-Caribbean population from St. Lucia, most patients realized a decrease in IOP of 40% that was sustained over 3 years, without medical therapy, Dr. Realini said.

    Sixty-one patients with OAG who were taking one glaucoma medication were included in the study. After a 30-day washout period, baseline IOP was determined in two measurements and patients were treated with bilateral 360° SLT. Patients were followed after treatment at 1 hour, 1 week, 1 and 3 months, and every 3 months thereafter through 36 months.


    NEXT: SLT rationale + Photo

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results